Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHF | ISIN: US89532M1018 | Ticker-Symbol:
NASDAQ
28.03.25
20:41 Uhr
6,480 US-Dollar
0,000
0,00 %
1-Jahres-Chart
TREVI THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TREVI THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TREVI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.03.Trevi Therapeutics (NASDAQ:TRVI) Stock Price Up 4.4% - Here's Why8
19.03.Stifel maintains Buy on Trevi Therapeutics stock, $15 target2
19.03.Wainwright maintains $12.50 target on Trevi Therapeutics stock1
18.03.Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates564Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development...
► Artikel lesen
TREVI THERAPEUTICS Aktie jetzt für 0€ handeln
18.03.Trevi Therapeutics GAAP EPS of -$0.11 beats by $0.013
18.03.Trevi Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Trevi Therapeutics, Inc. - 10-K, Annual Report2
18.03.Trevi Therapeutics, Inc. - 8-K, Current Report3
12.03.Traders Buy Large Volume of Call Options on Trevi Therapeutics (NASDAQ:TRVI)2
11.03.TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study1
10.03.Trevi Therapeutics, Inc. - 8-K, Current Report1
10.03.Leerink raises Trevi Therapeutics stock target to $111
10.03.Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps2
10.03.Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High After Analyst Upgrade10
10.03.Needham raises Trevi Therapeutics stock target to $253
10.03.Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges1
10.03.Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James3
10.03.Trevi Therapeutics stock soars on positive trial results2
10.03.Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough97Haduvio met the primary endpoint with a statistically-significant reduction (p Haduvio showed similar efficacy in patients with moderate or severe cough counts (p Haduvio...
► Artikel lesen
25.02.Trevi Therapeutics, Inc.: Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough68Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...
► Artikel lesen
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1